Shoulder Innovations  beats Q1 revenue estimates, lifts 2026 revenue forecast

Shoulder Innovations

13/05/2026 21:22

Overview

US shoulder implant maker's Q1 revenue rose 65% yr/yr, beating analyst expectations

Company raised full-year 2026 revenue outlook to $65-68 mln from $62-65 mln

Net loss widened to $8.4 mln due to higher operating expenses

Outlook

Shoulder Innovations raises 2026 net revenue guidance to $65 mln-$68 mln

Company expects 2026 net revenue growth of 37%-44% over 2025

Company cites commercial momentum and product launches as drivers for revised outlook

Result Drivers

IMPLANT VOLUME - Revenue growth was driven by a 51% increase in the number of implant systems sold and an increase in customers

HIGHER SELLING PRICE - Average selling price of implant systems rose 9% yr/yr to $7,650

NEW PRODUCT LAUNCH - Full commercial launch of the InSet I-135RFX Humeral Stem contributed to portfolio expansion

Company press release: ID:nPn8TLCfNa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$16.71 mln
$14.54 mln (4 Analysts)
Q1 EPS
-$0.41
Q1 Net Income
-$8.38 mln
Q1 Gross Profit
$12.99 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Shoulder Innovations Inc is $20.00, about 49.6% above its May 12 closing price of $13.37

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)